• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is There a Case for Cannabis in the Treatment of Pain?

Is There a Case for Cannabis in the Treatment of Pain?

August 30, 2019
Adrienne Grzenda, MD, PhD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adrienne Grzenda, MD, PhD. Dr. Grzenda has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Da Vita et al, JAMA Psychiatry 2018;75(11):1118-1127

Study Type: Meta-analysis of placebo-controlled trials

In the midst of the opioid epidemic, researchers are looking for new ways to treat chronic pain. Interestingly, states that have legalized medical marijuana have fewer opioid prescriptions but no clear reduction in mortality over time (Shover CL et al, Proc Natl Acad Sci U S A. 2019;116(26):12624-12626). Opioid users who smoke marijuana are less likely to drop out of maintenance treatment programs, while benzodiazepine use predicts worse outcomes in this population (Powell et al, J Health Econ 2018:58:29-42; Socías ME et al, Addiction 2018;113:2250-2258). Could marijuana have direct benefits in the treatment of pain?

To address this question, researchers analyzed 18 placebo-controlled trials of cannabinoids as a treatment for mechanically-induced pain in otherwise healthy subjects. A total of 442 participants were included. Mean age was 27 with equal numbers of men and women. Two-thirds of the studies involved synthetic tetrahydrocannabinol (THC), the cannabinoid responsible for the “high” in marijuana, or schedule-III analogues of THC, such as dronabinol and nabilone. The other third used plant-based cannabis. The majority (89%) used a cross-over design where subjects received both cannabinoids and placebo with a washout period between the doses.

Compared to placebo, cannabinoid administration was associated with a small increase in pain threshold and a small-to-medium increase in pain tolerance. However, it did not change overall pain intensity. Cannabinoids made people better able to withstand a greater pain burden, but only to a certain point. They also made the experience of pain less unpleasant (small-to-medium effect size), and this effect was strongest with plant-based cannabis. Unpleasantness is important because it may influence the progression from chronic pain to depression. No significant association was found between cannabinoid administration and hypersensitivity to pain. Gender did not significantly impact any of the outcomes.

The biggest limitation to the study is the lack of blinding as most subjects could probably guess whether or not they were “high.” Furthermore, it is unclear how well mechanically induced pain approximates real, chronic pain. Lastly, cannabidiol (CBD) was not included in the study. CBD is often praised by enthusiasts for its properties and was recently approved in a prescription form for intractable seizures (Epidiolex; see TCPR Jan 2019). Unlike THC, CBD produces no “high” and may have added antipsychotic effects.

TCPR’S TAKE
Despite the widespread use of THC for a variety of ailments, little data exist to support its many claimed benefits. Additionally, the risks, including psychosis, are too large to recommend it to patients as an alternative analgesic.
General Psychiatry
KEYWORDS cannabidiol cannabis marijuana opioids pain research research-update
    Adrienne Grzenda, MD, PhD.

    Who's Who? A Review of Delusional Misidentification Syndromes

    More from this author
    www.thecarlatreport.com
    Issue Date: August 30, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - How to Talk about Medication, TCPR, September 2019
    Is There a Case for Cannabis in the Treatment of Pain?
    Is Paxil the Best SSRI for Anxiety?
    A New Contraindication for Ambien and the Z-Hypnotics
    A New Way to Talk to Patients about Medication
    Mirtazapine Augmentation: Running Low on Rocket Fuel
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.